Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

Published:September 18, 2008DOI:

      Background & Aims

      The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized. This study evaluated the correlations between the Crohn's Disease Activity Index (CDAI), the Simple Endoscopic Score for Crohn's Disease (SES-CD), serum high-sensitivity C-reactive protein (hsCRP) (both phenotype and genotype) and interleukin-6 (IL-6), and fecal calprotectin and lactoferrin.


      A total of 164 patients with Crohn's disease undergoing colonoscopy were enrolled. The CDAI and SES-CD scores, serum hsCRP and IL-6, CRP and IL-6 genotypes, and fecal calprotectin and lactoferrin were measured.


      There were no significant associations between the CDAI and SES-CD scores (Spearman rank correlation coefficient, 0.15) or between the CDAI scores and the serum concentrations of hsCRP and IL-6, or the fecal concentrations of calprotectin and lactoferrin. In contrast, the serum hsCRP and IL-6 concentrations and the fecal calprotectin and lactoferrin concentrations were significantly higher in patients with more severe endoscopic disease activity (SES-CD score > 7 points) (P < .001 for all comparisons). The CRP 717 mutant homozygote and heterozygote status was associated with significantly lower concentrations of hsCRP (P = .02). There was a trend toward higher hsCRP concentrations in the CRP 286 heterozygous adenine mutant-type mutant genotype, but this did not reach statistical significance.


      Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease. Stimulated hsCRP concentration is affected significantly by select genetic polymorphisms.

      Abbreviations used in this paper:

      CDAI (Crohn's Disease Activity Index), Cp (calprotectin), CRP (C-reactive protein), hsCRP (high-sensitivity C-reactive protein), IBD (inflammatory bowel disease), IL-6 (interleukin 6), Lf (lactoferrin), SES-CD (Simple Endoscopic Score for Crohn's Disease), SNP (single nucleotide polymorphism), TNF (tumor necrosis factor)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sandborn W.J.
        • Feagan B.G.
        • Hanauer S.B.
        • et al.
        A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
        Gastroenterology. 2002; 122: 512-530
        • Best W.R.
        • Becktel J.M.
        • Singleton J.W.
        • et al.
        Development of a Crohn's disease activity index.
        Gastroenterology. 1976; 70: 439-444
        • Mary J.
        • Modigliani R.
        Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study.
        Gut. 1989; 30: 983-989
        • Modigliani R.
        • Mary J.
        • Simon J.F.
        • et al.
        Clinical, biological and endoscopic picture of attacks of Crohn's disease; evolution on prednisolone.
        Gastroenterology. 1990; 98: 811-818
        • Rutgeerts P.
        • Diamond R.H.
        • Bala M.
        • et al.
        Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
        Gastrointest Endosc. 2006; 63: 433-442
        • D'Haens G.
        • Norman M.
        • Baert F.
        • et al.
        Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse.
        Gastroenterology. 2002; 122: A100
        • Daperno M.
        • D'Haens G.
        • Van Assche G.
        • et al.
        Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
        Gastrointest Endosc. 2004; 60: 505-512
        • Desai D.
        • Faubion W.A.
        • Sandborn W.J.
        Review article: biological activity markers in inflammatory bowel disease.
        Aliment Pharmacol Ther. 2007; 25: 247-255
        • Volkanis J.
        Human C-reactive protein: expression, structure and function.
        Mol Immunol. 2001; 38: 189-197
        • Boirivant M.
        • Leoni M.
        • Taricotti D.
        • et al.
        The clinical significance of serum C reactive protein levels in Crohn's disease.
        J Clin Gastroenterol. 1988; 10: 401-405
        • Andre C.
        • Descos L.
        • Landais P.
        • et al.
        Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.
        Gut. 1981; 22: 571-574
        • Buckell N.
        • Leonnard-Jones J.
        • Hernandez M.
        • et al.
        Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management.
        Gut. 1979; 20: 22-27
        • Brignola C.
        • Lanfranchi G.A.
        • Campieri M.
        • et al.
        Importance of laboratory parameters in the evaluation of Crohn's disease activity.
        J Clin Gastroenterol. 1986; 8: 245-248
        • Fagan E.
        • Dyck R.
        • Maton P.
        • et al.
        Serum levels of C-reactive protein on Crohn's disease and ulcerative.
        colitis. 1982; 12: 351-359
        • Niederau C.
        • Backmerhoff F.
        • Schumacher B.
        • et al.
        Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
        Hepatogastroenterology. 1997; 44: 90-107
        • Cao H.
        • Hegele R.
        Human C-reactive protein (CRP) 1059G/C polymorphism.
        J Hum Genet. 2000; 45: 100-101
        • Brull D.J.
        • Serrano N.
        • Zito F.
        • et al.
        Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease.
        Arterioscler Thromb Vasc Biol. 2003; 23: 2063-2069
        • Chen J.
        • Zhao J.
        • Huang J.
        • et al.
        -717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study.
        J Mol Med. 2005; 83: 72-78
        • Gander M.L.
        • Fischer J.E.
        • Maly F.E.
        • et al.
        Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)-alpha gene promoter site on plasma levels of TNF-alpha and C-reactive protein in smokers: a cross-sectional study.
        BMC Cardiovasc Disord. 2004; 4: 17
        • Haukim N.
        • Bidwell J.L.
        • Smith A.J.
        • et al.
        Cytokine gene polymorphism in human disease: on-line databases, supplement 2.
        Genes Immun. 2002; 3: 313-330
        • Kovacs A.
        • Green F.
        • Hansson L.O.
        • et al.
        A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein.
        Atherosclerosis. 2005; 178: 193-198
        • Szalai A.J.
        • McCrory M.A.
        • Cooper G.S.
        • et al.
        Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene.
        Genes Immun. 2002; 3: 14-19
        • Zee R.Y.
        • Ridker P.M.
        Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis.
        Atherosclerosis. 2002; 162: 217-219
        • Margaglione M.
        • Bossone A.
        • Cappucci G.
        • et al.
        The effect of the interleukin-6 C/G -174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels.
        Haematologica. 2001; 86: 199-204
        • Tilg H.
        • Dinarello C.A.
        • Mier J.W.
        IL-6 and APPs: anti-inflammatory and immunosuppressive mediators.
        Immunol Today. 1997; 18: 428-432
        • Mahida Y.R.
        • Kurlac L.
        • Gallagher A.
        • et al.
        High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.
        Gut. 1991; 32: 1531-1534
        • Mitsuyama K.
        • Sasaki E.
        • Toyonaga A.
        • et al.
        Colonic mucosal interleukin-6 in inflammatory bowel disease.
        Digestion. 1991; 50: 104-111
        • Roseth A.G.
        • Fagerhol M.K.
        • Aadland E.
        • et al.
        Assessment of the neutrophil dominating protein calprotectin in feces.
        Scand J Gastroenterol. 1992; 27: 793-798
        • Steinbakk M.
        • Naess-Andresen C.F.
        • Lingaas E.
        • et al.
        Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin.
        Lancet. 1990; 336: 763-765
        • Kane S.V.
        • Sandborn W.J.
        • Rufo P.A.
        • et al.
        Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
        Am J Gastroenterol. 2003; 98: 1309-1314
        • Tibble J.A.
        • Sigthorsson G.
        • Foster R.
        • et al.
        Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
        Gastroenterology. 2002; 123: 450-460
        • Roseth A.G.
        • Aadland E.
        • Jahnsen J.
        • et al.
        Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein.
        Digestion. 1997; 58: 176-180
        • Frenz M.B.
        • Dunckley P.
        • Camporota L.
        • et al.
        Comparison between prospective and retrospective evaluation of Crohn's disease activity index.
        Am J Gastroenterol. 2005; 100: 1117-1120
        • Solem C.A.
        • Loftus Jr, E.V.
        • Tremaine W.J.
        • et al.
        Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
        Inflamm Bowel Dis. 2005; 11: 707-712
        • Denis M.A.
        • Reenaers C.
        • Fontaine F.
        • et al.
        Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level.
        Inflamm Bowel Dis. 2007; 13: 1100-1105
        • Willot S.
        • Vermeire S.
        • Ohresser M.
        • et al.
        No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
        Pharmacogenet Genomics. 2006; 16: 37-42
        • Wolford J.
        • Gruber D.
        • Victoria M.
        • et al.
        A C-reactive polymorphism is associated with type 2 diabetes in Pima Indians.
        Mol Genet Metab. 2003; 78: 136-144
        • Pepys M.B.
        • Hirschfield G.M.
        C-reactive protein: a critical update.
        J Clin Invest. 2003; 111: 1805-1812
        • Tibble J.A.
        • Sigthorsson G.
        • Bridger S.
        • et al.
        Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.
        Gastroenterology. 2000; 119: 15-22
        • Cellier C.
        • Sahmoud T.
        • Froguel E.
        • et al.
        Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease.
        Gut. 1994; 35: 231-235
        • Poullis A.
        • Zar S.
        • Sundaram K.
        • et al.
        A new, highly sensitive assay for C-reactive protein can aid in the differentiation of inflammatory bowel disorders from constipation and diarrhea-predominant functional bowel disorders.
        Eur J Gastroenterol Hepatol. 2002; 14: 409-412
        • Moskovitz D.N.
        • Daperno M.
        • Van assche G.A.
        Defining and validating cut-offs for the simple endoscopic score for Crohn's disease.
        Gastroenterology. 2007; 132: A-S1097